Johnson & Johnson (JNJ) Deferred Taxes (2009 - 2026)
Johnson & Johnson recorded quarterly Deferred Taxes of $159.0 million in Q1 2026, up 104.32% quarter-over-quarter from -$3.7 billion in Q4 2025, and down 92.68% year-over-year from $2.2 billion in Q1 2025.
Johnson & Johnson's Deferred Taxes history runs 18 years deep, the most recent figure standing at $159.0 million for Q1 2026.
- In Q1 2026, Deferred Taxes fell 92.68% year-over-year to $159.0 million; the TTM figure through Mar 2026 stood at -$475.0 million (down 130.63% YoY), while the FY2025 annual figure was $1.5 billion, up 170.45% from the prior year.
- Deferred Taxes came in at $159.0 million for Q1 2026 at Johnson & Johnson, up from -$3.7 billion in the prior quarter.
- In the past five years, Deferred Taxes ranged from a high of $2.2 billion in Q3 2025 to a low of -$3.7 billion in Q4 2025.
- A 5-year average of -$313.7 million and a median of -$16.0 million in 2024 frame the typical range for Deferred Taxes.
- On a YoY basis, Deferred Taxes climbed as much as 2364.44% in 2025 and fell as far as 22881.25% in 2025.
- Johnson & Johnson's Deferred Taxes stood at -$926.0 million in 2022, then plunged by 160.48% to -$2.4 billion in 2023, then surged by 99.34% to -$16.0 million in 2024, then sank by 22881.25% to -$3.7 billion in 2025, then surged by 104.32% to $159.0 million in 2026.
- According to Business Quant data, Deferred Taxes over the past three periods registered $159.0 million, -$3.7 billion, and $2.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 1.48 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 159.00 Mn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 137.00 Mn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -315.00 Mn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | -176.00 Mn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 179.00 Mn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | -12.00 Mn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 161.00 Mn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 159.00 Mn |
| Dec 28, 2025 | -3.68 Bn |
| Sep 28, 2025 | 2.22 Bn |
| Jun 29, 2025 | 825.00 Mn |
| Mar 30, 2025 | 2.17 Bn |
| Dec 29, 2024 | -16.00 Mn |
| Sep 29, 2024 | 90.00 Mn |
| Jun 30, 2024 | -695.00 Mn |
| Mar 31, 2024 | -1.56 Bn |
| Dec 31, 2023 | -2.41 Bn |
| Oct 1, 2023 | 560.00 Mn |
| Jul 2, 2023 | -799.00 Mn |
| Apr 2, 2023 | -1.54 Bn |
| Jan 1, 2023 | 901.00 Mn |
| Apr 3, 2022 | -926.00 Mn |
| Oct 3, 2021 | -1.88 Bn |
| Jul 4, 2021 | 45.00 Mn |
| Apr 4, 2021 | -730.00 Mn |
| Jan 3, 2021 | -903.00 Mn |
| Sep 27, 2020 | 190.00 Mn |
| Jun 28, 2020 | -482.00 Mn |
| Mar 29, 2020 | 54.00 Mn |
| Dec 29, 2019 | -350.00 Mn |
| Sep 29, 2019 | -1.43 Bn |
| Jun 30, 2019 | -332.00 Mn |
| Mar 31, 2019 | -362.00 Mn |
| Dec 30, 2018 | 1.90 Bn |
| Sep 30, 2018 | 338.00 Mn |
| Jul 1, 2018 | -329.00 Mn |
| Apr 1, 2018 | 44.00 Mn |
| Dec 31, 2017 | 2.81 Bn |
| Oct 1, 2017 | -335.00 Mn |
| Jul 2, 2017 | -45.00 Mn |
| Apr 2, 2017 | -27.00 Mn |
| Jan 1, 2017 | -574.00 Mn |
| Apr 3, 2016 | 393.00 Mn |
| Sep 27, 2015 | -51.00 Mn |
| Jun 28, 2015 | -261.00 Mn |
| Mar 29, 2015 | 545.00 Mn |
| Dec 28, 2014 | 144.00 Mn |
| Sep 28, 2014 | -296.00 Mn |
| Jun 29, 2014 | 98.00 Mn |
| Mar 30, 2014 | 495.00 Mn |
| Dec 29, 2013 | -383.00 Mn |
| Sep 29, 2013 | -316.00 Mn |
| Jun 30, 2013 | -273.00 Mn |
| Mar 31, 2013 | 365.00 Mn |
| Dec 30, 2012 | 285.00 Mn |
| Sep 30, 2012 | 187.00 Mn |
| Jul 1, 2012 | -1.07 Bn |
| Apr 1, 2012 | 557.00 Mn |
| Jan 1, 2012 | -1.48 Bn |
| Apr 3, 2011 | -4.00 Mn |
| Oct 3, 2010 | 40.00 Mn |
| Jul 4, 2010 | -356.00 Mn |
| Apr 4, 2010 | 960.00 Mn |
| Jan 3, 2010 | -977.00 Mn |
| Sep 27, 2009 | -104.00 Mn |
| Jun 28, 2009 | -567.00 Mn |
| Mar 29, 2009 | 1.21 Bn |